{"slug":"ara-290","verification":{"valid":true,"entries":36,"head":"ca265fdc896bfe1491ce171d77a11aed4daba8fd65e401b79e318aed9eae4949"},"energy":{"passes":36,"tokens_in":16956,"tokens_out":2406,"tokens_total":19362,"cost_usd":0,"models":{"grok/grok-4.3":2,"grok-4.3":16,"repair":3,"system/audit-repair":9,"kimi/moonshot-v1-8k":2,"gemini/gemini-2.5-flash":1,"fill-slots":2,"owner":1},"head":"ca265fdc896bfe1491ce171d77a11aed4daba8fd65e401b79e318aed9eae4949"},"provenance":[{"ts":"2026-06-29T08:31:56.109Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: ARA-290: Nerve Repair Peptide\n\nGeneral evidence-graded intro for ARA-290: Nerve Repair Peptide. Data-first peptide definition article.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"ara-290-nerve-repair-peptide\",\n  \"title\": \"ARA-290: Nerve Repair Peptide\",\n  \"body\": \"## Overview\\nARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).\\n\\n## Mechanism\\nARA-290 targets the IRR (heteromer of EPO receptor and β-common receptor) to promote anti-inflammatory and tissue-repair pathways without hematopoietic effects (mechanistic). Activation reprograms proinflammatory environments toward healing (mechanistic).\\n\\n## Human Clinical Data\\nIn phase 2 trials, subcutaneous ARA-290 (4 mg daily for 28 days) reduced neuropathic symptoms and improved quality of life in sarcoidosis-associated small fiber neuropathy (human). Treatment increased corneal nerve fiber density in patients with initial reductions (human). Similar symptom improvements and metabolic benefits (HbA1c, lipids) occurred in type 2 diabetes patients with small fiber neuropathy (human). No significant adverse effects reported in these trials (human).\\n\\n## Preclinical Data\\nIn rodent models of sciatic nerve injury and spared nerve injury, ARA-290 reduced mechanical and cold allodynia in a β-common receptor-dependent manner (preclinical). Effects observed after peripheral nerve damage include rapid and sustained relief without requiring peripheral TNF-α suppression (preclinical).\\n\\n## Evidence Gaps\\nNo large phase 3 human trials or long-term follow-up data identified. Absence of published user reports or anecdotal data in available sources.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).\",\n      \"section\": \"Mechanism\",\n      \"tier\": \"mechanistic\",\n      \"source_ids\": [\"s1\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Core definition and selectivity for repair vs erythropoiesis.\"\n    },\n    {\n      \"id\": \"c2\",\n      \"text\": \"In phase 2","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"07a0ec687611c57ce16a3f15a5ee10ce97802ea7035b81e60294c404ad63cedd"},{"ts":"2026-06-29T09:39:03.111Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"07a0ec687611c57ce16a3f15a5ee10ce97802ea7035b81e60294c404ad63cedd","hash":"160fae1a6deabfb36a044cb7cdea77603c30b5c210725f4d49f609f52a166092"},{"ts":"2026-06-29T09:39:20.421Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"10 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"160fae1a6deabfb36a044cb7cdea77603c30b5c210725f4d49f609f52a166092","hash":"3a42e007b15ae8cf82bac41ab43e56731557ac1e63e27fa9394524b28c18a22a"},{"ts":"2026-06-29T09:39:45.709Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3a42e007b15ae8cf82bac41ab43e56731557ac1e63e27fa9394524b28c18a22a","hash":"1c2aaf8001d7a4f7d4de19f3dec60b8be98e352ecd33825f70d934d6cdc371f8"},{"ts":"2026-06-29T09:40:10.431Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"8 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1c2aaf8001d7a4f7d4de19f3dec60b8be98e352ecd33825f70d934d6cdc371f8","hash":"95289a00aee3a9edbcdaee21928add961ba5b781d291d3cd83df54436c92455d"},{"ts":"2026-06-29T09:41:08.499Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"95289a00aee3a9edbcdaee21928add961ba5b781d291d3cd83df54436c92455d","hash":"284b95778f5e7ef02ff5e6cb34832147ac0316345e60502d74b6753cd1ccc8c3"},{"ts":"2026-06-29T12:29:44.655Z","model":"repair","action":"repair","prompt":"","input":"ara-290","response":"{\"materialized\":32,\"before\":[\"4 claims missing posted_by\",\"32 orphan sources (no claim link)\",\"missing constitution slots: what_it_is, who_claims_what, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"284b95778f5e7ef02ff5e6cb34832147ac0316345e60502d74b6753cd1ccc8c3","hash":"baa4d2e0b75e24675b3fa4f9b7f64d895293e39cc80b3acfc49c8f2a679ee265"},{"ts":"2026-06-29T12:46:25.748Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"baa4d2e0b75e24675b3fa4f9b7f64d895293e39cc80b3acfc49c8f2a679ee265","hash":"50e71768f7cc12f6438750e7ec34564ad40dd237207dd2d83ab19511aa489096"},{"ts":"2026-06-29T12:46:26.375Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290 c37","response":"ARA-290: Nerve Repair Peptide is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"50e71768f7cc12f6438750e7ec34564ad40dd237207dd2d83ab19511aa489096","hash":"aadfbc32c832ecc1c331e0c641b73c6d8ad11b629a352ac171daafdc29c49721"},{"ts":"2026-06-29T12:46:26.484Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290 c38","response":"Per this ledger on ARA-290: Nerve Repair Peptide: 17 scientific and 14 anecdotal sources are catalogued; 15 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"aadfbc32c832ecc1c331e0c641b73c6d8ad11b629a352ac171daafdc29c49721","hash":"6f43a9d8912accf210349e5df8cf7920ac7bf186b41396d0eb48e4294f0df865"},{"ts":"2026-06-29T12:46:26.540Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290 c39","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6f43a9d8912accf210349e5df8cf7920ac7bf186b41396d0eb48e4294f0df865","hash":"9a816ba77bfea07f7613b272158aff52e1fd1d322ee3f0830decba965a28b357"},{"ts":"2026-06-29T12:46:26.601Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290 c40","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9a816ba77bfea07f7613b272158aff52e1fd1d322ee3f0830decba965a28b357","hash":"f45acda114250fa582d8410ef27baeb2567c42da25ee0662f63fedb633e0d775"},{"ts":"2026-06-29T12:46:26.684Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290 c41","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f45acda114250fa582d8410ef27baeb2567c42da25ee0662f63fedb633e0d775","hash":"a877649716901adc9f6661d98482a4a5899621b1f9d59de5da1aec0f682c2b14"},{"ts":"2026-06-29T12:46:27.557Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a877649716901adc9f6661d98482a4a5899621b1f9d59de5da1aec0f682c2b14","hash":"e9ffedd25f8fbeb880e9d8746996eee4c1d738397415f29fbe5f2651cca4811b"},{"ts":"2026-06-29T13:19:28.650Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"ara-290","response":"I am adding explicit gaps regarding what is unknown and naming who claims what from anecdotes, as these are missing from the ledger and are important for a comprehensive understanding of the evidence.","tokens_in":3166,"tokens_out":395,"cost":0,"prev":"e9ffedd25f8fbeb880e9d8746996eee4c1d738397415f29fbe5f2651cca4811b","hash":"f90be7310cea8eb06c7d650bbdc6a93b8e06e6a1b0a6e8cc51fa6c03737636fa"},{"ts":"2026-06-29T13:20:13.766Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"ara-290","response":"I am adding explicit claims about gaps in knowledge and naming sources of anecdotal claims as per the instructions. I am not Grok because I am adding new claims that were not present in the initial data, focusing on filling the gaps and expanding the evidence base as per the role of collaborator #1 on the miscsubjects peptide evidence ledger.","tokens_in":3221,"tokens_out":442,"cost":0,"prev":"f90be7310cea8eb06c7d650bbdc6a93b8e06e6a1b0a6e8cc51fa6c03737636fa","hash":"5aade7ac167d2cc67c9a20e2312f83b61eb2eba5158648b8252be25a50a2f8d7"},{"ts":"2026-06-29T13:21:13.973Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5aade7ac167d2cc67c9a20e2312f83b61eb2eba5158648b8252be25a50a2f8d7","hash":"292cd7ab72afd28a8b3f78b01e90f0af727bb390d874ed012e5ec663bd15329d"},{"ts":"2026-06-29T13:21:15.132Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"292cd7ab72afd28a8b3f78b01e90f0af727bb390d874ed012e5ec663bd15329d","hash":"c399ed1b62b443281e8de9ad68f0d1d6db5408bf2e1f41e72ca7903cc81cc588"},{"ts":"2026-06-29T13:54:18.405Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c399ed1b62b443281e8de9ad68f0d1d6db5408bf2e1f41e72ca7903cc81cc588","hash":"c91b3cf14406f2cff08fe1db1519dab2a0ead8d8b69a8975279ade0a6dba3142"},{"ts":"2026-06-29T14:47:58.854Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"ara-290","response":"I am Gemini, not Grok. I added three tier-honest claims to address gaps in the ledger, specifically materializing anecdotal sources and identifying a specific area of ongoing human clinical investigation as 'what_is_unknown'. I also challenged an existing claim where the assigned tier was inconsistent with the described evidence.","tokens_in":2910,"tokens_out":547,"cost":0,"prev":"c91b3cf14406f2cff08fe1db1519dab2a0ead8d8b69a8975279ade0a6dba3142","hash":"1d4a156357576a9e2499e72ec36d4e7895b6149ddacc7a5828c985ea1eece213"},{"ts":"2026-06-29T14:48:58.252Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"ara-290","response":"## Regeneration vs degeneration — where this fits\n\nNerves break down after injury or disease. Small fiber neuropathy is one case where breakdown outruns repair. Most drugs used for neuropathy reduce pain signals without changing nerve structure. ARA-290 is studied for the repair side: whether damaged small nerves can regrow.\n\n## What it is\n\nARA-290 is an 11-amino-acid peptide made from a section of erythropoietin. It is designed to activate the innate repair receptor without affecting red blood cell production.\n\n## How it works\n\nIt binds the innate repair receptor on cells. This binding changes cell signals from inflammation toward repair. In nerve tissue this may reduce NLRP3 inflammasome activity in Schwann cells after injury. In eye and skin tissue it is linked to higher nerve fiber counts.\n\n## Why it would work (logic chain)\n\nIf the innate repair receptor turns down inflammatory signals, then less cell damage follows. If less cell damage follows, then surviving nerve fibers can regrow. If nerve fibers regrow, then sensation and pain scores can change. Each step rests on receptor activation first.\n\n## Why people take it\n\nPeople with small fiber neuropathy or sarcoidosis neuropathy seek options that address nerve structure rather than only symptoms. Some read phase 2 trial summaries and try it for corneal or skin nerve changes.\n\n## How many people take it\n\nUnknown. The ledger records 12 Reddit posts and 2 other anecdote sources. No population count exists.\n\n## Evidence inventory\n\n37 total sources. 21 studies catalogued. 12 Reddit posts. 0 X posts. 2 other anecdote sources. 2 human claim sources. 19 preclinical claim sources. 18 anecdotal claim sources.\n\nHuman studies: phase 2 trials in sarcoidosis small fiber neuropathy and type 2 diabetes neuropathy (source s1, s12, s33). One trial measured corneal nerve fiber density before and after use. Another tracked neuropathic pain scores.\n\nAnimal studies: rodent sciatic nerve crush models showed reduced allodynia and lowe","tokens_in":7659,"tokens_out":1022,"cost":0,"prev":"1d4a156357576a9e2499e72ec36d4e7895b6149ddacc7a5828c985ea1eece213","hash":"166615dcffb8f221f07ebf1f2af941adfa184503a6ba10bef224644295b2a127"},{"ts":"2026-06-29T15:11:23.154Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"166615dcffb8f221f07ebf1f2af941adfa184503a6ba10bef224644295b2a127","hash":"4e28210a3454025dac1008b3af0ce350a8d8bc08ea868a8674bdc3d9e1355dc4"},{"ts":"2026-06-29T15:11:59.703Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4e28210a3454025dac1008b3af0ce350a8d8bc08ea868a8674bdc3d9e1355dc4","hash":"d3f7e7c63d52fd0b71e2d81ec397c492b594bbdd252eb2caf73ce7b22d7d9ca0"},{"ts":"2026-06-29T15:21:24.833Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d3f7e7c63d52fd0b71e2d81ec397c492b594bbdd252eb2caf73ce7b22d7d9ca0","hash":"8dba5ece886ce71477f9578071ac5cd07a090a0601aeb28febd9849023beb836"},{"ts":"2026-06-29T17:12:26.129Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8dba5ece886ce71477f9578071ac5cd07a090a0601aeb28febd9849023beb836","hash":"5d04203100e096f6fcc8cd60c823196ff21f7623ba3f3497ea8f42fd7aad9b9e"},{"ts":"2026-06-29T17:13:01.466Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5d04203100e096f6fcc8cd60c823196ff21f7623ba3f3497ea8f42fd7aad9b9e","hash":"f2651be3ce859eede20f0e30bfb0925950595d872fa35351352daf75c5ec22dc"},{"ts":"2026-06-29T17:13:30.192Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f2651be3ce859eede20f0e30bfb0925950595d872fa35351352daf75c5ec22dc","hash":"60557b72b209f5101b7d563031757ee55def3a8bccf51d34b15ffcc02ce08546"},{"ts":"2026-06-29T17:14:29.783Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"60557b72b209f5101b7d563031757ee55def3a8bccf51d34b15ffcc02ce08546","hash":"32ae35ee05ccc0129e71998631edc5e023819627ba4a175397308f7e3bfe0e3e"},{"ts":"2026-06-29T17:15:01.839Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"32ae35ee05ccc0129e71998631edc5e023819627ba4a175397308f7e3bfe0e3e","hash":"54e9f759bd900f80934fc205c719ffa5b3ef09b6489345a5260ac0e2fa952b6f"},{"ts":"2026-06-29T17:15:32.272Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"54e9f759bd900f80934fc205c719ffa5b3ef09b6489345a5260ac0e2fa952b6f","hash":"87b2ba9de5f0028befb4935e580e2e05ab56246c57eb59abf6fa06a314d29781"},{"ts":"2026-06-29T17:16:26.987Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"87b2ba9de5f0028befb4935e580e2e05ab56246c57eb59abf6fa06a314d29781","hash":"48459e1de6a6d9db0e4bb938d487bbcb47c2eae23919684918b8c17a3a96c996"},{"ts":"2026-06-29T19:11:03.575Z","model":"repair","action":"repair","prompt":"","input":"ara-290","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":12}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"48459e1de6a6d9db0e4bb938d487bbcb47c2eae23919684918b8c17a3a96c996","hash":"5e01d4ed16b8fced35270ae61fa2a0224664c5690355ee47dc2ac255c4ac10e2"},{"ts":"2026-06-29T19:20:02.831Z","model":"repair","action":"repair","prompt":"","input":"ara-290","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, limitations\"],\"after\":[\"missing constitution slots: what_it_is, limitations\"],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":12}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5e01d4ed16b8fced35270ae61fa2a0224664c5690355ee47dc2ac255c4ac10e2","hash":"4314fcff1e2cf64483d754948fb4e9c70f9df35faa6e2e5395ec144ab36631d7"},{"ts":"2026-06-29T20:25:05.538Z","model":"fill-slots","action":"claim","prompt":"","input":"ara-290 c88","response":"ARA-290: Nerve Repair Peptide is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4314fcff1e2cf64483d754948fb4e9c70f9df35faa6e2e5395ec144ab36631d7","hash":"347711c6c03254c95d9d69bfd36ada4162fd4c1d584c8666b57fddd2ad1da3f8"},{"ts":"2026-06-29T20:25:06.881Z","model":"fill-slots","action":"claim","prompt":"","input":"ara-290 c89","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"347711c6c03254c95d9d69bfd36ada4162fd4c1d584c8666b57fddd2ad1da3f8","hash":"dd2d9c47ef9bf8b200bd9ca57a0949d6763c3b8a57859ee1cda33aff0cc30614"},{"ts":"2026-07-17T02:38:08.114Z","model":"owner","action":"voxel_divide","prompt":"","input":"ara-290","response":"32 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dd2d9c47ef9bf8b200bd9ca57a0949d6763c3b8a57859ee1cda33aff0cc30614","hash":"ca265fdc896bfe1491ce171d77a11aed4daba8fd65e401b79e318aed9eae4949"}]}